Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

AL3818 hydrochloride monotherapy in subjects with metastatic or advanced...

Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA

AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma ( Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA )

Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial...

Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA

Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma ( Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA )

Highlights from ASCO 2021

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Highlights from ASCO 2021 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal...

Prof Daniel Catenacci - University of Chicago, Chicago, USA

Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma ( Prof Daniel Catenacci - University of Chicago, Chicago, USA )

ASCO 2021: Latest on PARPi and other treatments for mCRPC

Dr Neal Shore and Prof Oliver Sartor

ASCO 2021: Latest on PARPi and other treatments for mCRPC ( Dr Neal Shore and Prof Oliver Sartor )

mCRPC: Latest developments in diagnostics and combination therapies

Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor

mCRPC: Latest developments in diagnostics and combination therapies ( Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor )

ASCO 2021: Renal cancer roundup

Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA

ASCO 2021: Renal cancer roundup ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )

Olaparib improves disease-free survival in high-risk early-stage HER2-negative...

Prof Andrew Tutt - Institute of Cancer Research, London, UK

Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations ( Prof Andrew Tutt - Institute of Cancer Research, London, UK )

OncoAlert and ecancer weekly roundup for April 26 - May 3, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for April 26 - May 3, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

UpSwinG: Real-world, non-interventional cohort study on TKI activity in...

Dr Satoru Miura - Niigata Cancer Center Hospital, Niigata, Japan

UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients with EGFRm NSCLC with uncommon mutations ( Dr Satoru Miura - Niigata Cancer Center Hospital, Niigata, Japan )

Efficacy and early discontinuation predictors in NSCLC patients receiving...

Dr Giulia Pasello - University of Padova, Padua, Italy

Efficacy and early discontinuation predictors in NSCLC patients receiving nivolumab ( Dr Giulia Pasello - University of Padova, Padua, Italy )

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA...

Dr Matthew Marx - Mirati Therapeutics, San Diego, USA

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours ( Dr Matthew Marx - Mirati Therapeutics, San Diego, USA )

More from ecancer